Coronary artery disease (CAD) is the most prevalent form of heart disease, affecting approximately 18 million adults in the ...

Patients with depression may develop atherosclerotic cardiovascular disease earlier and start treatment more often than those ...

NEW ORLEANS -- Adding the PCSK9 inhibitor evolocumab (Repatha) to stable lipid-lowering therapy reduced major adverse cardiac ...

Hypereosinophilic syndrome (HES) is a heterogeneous disorder characterised by persistent, abnormal eosinophil elevation in ...

NEW ORLEANS -- The investigational oral PCSK9 inhibitor enlicitide reduced low-density lipoprotein (LDL) cholesterol in ...

A promising “two-in-one” experimental drug could tackle both type 2 diabetes and heart disease by slashing cholesterol and ...

The prevalence of overweight and obesity has reached pandemic proportions, affecting more than 1 billion people worldwide; it ...

Results from the international VESALIUS-CV (TIMI 66) clinical trial found that among adults with atherosclerotic cardiovascular disease (ASCVD) or diabetes and no history of a prior heart attack or ...

The cholesterol-lowering drug is part of a suite of medicines that also includes MariTide and that Amgen Chief Medical ...

More than 70% of people over 70 years old will one day develop cardiovascular disease, highlighting the need for effective ...

Diabetes can lead to kidney failure, cardiovascular disease, stroke, diabetic retinopathy and others. Read on to know ...

Some bacterial species, particularly some linked to inflammation, are associated with coronary artery disease, a common form ...